MedTrace Logo

Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

NCT04548401 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-09-14

No results posted yet for this study

Summary

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage

Interventions

DRUG

Antiplatelet Drug

aspirin and/or clopidogrel or ticagrelor

Sponsors & Collaborators

  • Nanjing Medical University

    lead OTHER

Principal Investigators

  • Hai Bin Shi, MD · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-10-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04548401 on ClinicalTrials.gov